Athira Pharma (ATHA) stock forecast for 2024, 2025, 2030

Share this:
Disclaimer

Disclaimer

All information on this page is published ‘as is’ and for information purposes alone. The information is not intended for trading or advice of financial, investment, tax, legal, accounting or any kind of nature. Before starting to trade, please contact your broker or a financial advisor to check the quotes, evaluate forecasts or the opinion of the author of the article. Our company is not an investment consultant, financial advisor or a broker for transactions involving securities. No information shall be viewed as investment advice, recommendation or offer of our company to buy, hold or sell securities or financial products. Our company does not provide guarantees and does not express opinions about appropriateness or suitability of investments.

No information shall be regarded as investment advice (general or individual). Financial products or transactions mentioned in such information may not be suitable for your investment portfolio and may not meet your investment targets and expectations. You are solely responsible for any decision regarding financial products or transactions and you shall independently determine whether they are suitable for you, taking into account your interests, investment targets, investment horizon and tolerable risk level. Our company shall not bear any responsibility for the losses caused by financial transactions or investments in financial products mentioned on our website. We do not recommend making investment decisions guided solely by this information.

The information on our website is provided by stock exchanges, brokers and other content providers, and, in some cases, may arrive with a delay. Our company does not verify such information and shall waive any liability related to it.

Our company and our information and content providers, financial exchanges, brokers and also all affiliated companies and business partners: a) expressly waive any responsibility for the accuracy, validity and completeness of any data; b) shall not be liable for any mistakes, omissions or other flaws on such information, for delays and interruptions in their display, as well as for actions taken based on such information. Neither our company nor our information providers shall be liable for the damage caused by the use of the information provided here. The term ‘business partners’ in this case shall not imply any partnership or agency relationships as well as the creation of a joint venture between our company and any other organization.

You hereby confirm that you shall not copy, modify, reformat, download, store, reproduce, process, transfer or distribute any information published here or use such information for commercial purposes without prior written consent.

Traders Union as well as its external information and content providers retain exclusive copyright to the provided information.

Our company shall not be liable for the products and services advertised on our website.

General websites Disclaimer:

Traders Union (tradersunion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it. Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

Start Trading 3,000+ Stocks Online
Your capital is at risk.

eToro - Best Broker to Trade Stocks Online

Athira Pharma (ATHA) is a biopharmaceutical company founded in 2011, involved in research of treatment methods of Parkinson’s and Alzheimer’s diseases. Athira Pharma is a company of very narrow specialization, which has not yet completed the final stage of developing and clinically testing small “molecules to restore neuronal health”. The funding for the research is provided by government funds and private investment groups (Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, and others).

1

Current ATHA stock price $1.95.

2

According to analytical forecasts, the price of ATHA stocks may reach $2.94 by the end of 2024, and it is expected to be - $11.18 by the end of 2029.

3

Based on technical analysis indicators, the recommendation for the 1H (one-hour) timeframe is Strong Sell, and for the 1D (one-day) timeframe - Strong Sell.

Following the IPO, Athira Pharma stock price grew by 2.2 times, and then gradually declined. In the past years, the ATHA stock price dropped more than tenfold compared to the all-time-high.


Traders Union analysts prepared short and long-term Athira Pharma stock price forecasts for 2024, 2025, and 2030. This page features financial indicators, technical analysis indicators and provides information about the factors influencing the stock price.

NOTE!

On this page, you will find the latest information about current prices, updated and new forecasts for short and long-term intervals:

  • Asset quotes are updated every minute.
  • Price chart is updated every minute.
  • Technical indicator data is updated according to the time frame. For example, on M5, the data is updated every 5 minutes.
  • Medium and long-term forecasts are updated every hour.
  • Financial reporting data is updated quarterly.

Data for fundamental analysis of Athira Pharma stock

In this section you will learn about the basic statistics of Athira Pharma and other data for fundamental analysis. The section provides key financial indicators of the company as well as main multipliers.


Basic indicators contain information about the company that provides a general idea of its operation and position in the market.



Basic indicators
Industry
Biotechnology
Sector
Healthcare
Number of employees
65
Latest dividend payment date
-
Dividend amount
-
Market cap
73.59M
Net income
-27.29M
52-week low
1.33
52-week high
4.3
Beta coefficient
2.78


Key financial indicators of Athira Pharma contain general information about the financial condition of the company. For analysis, current values are compared to the values of previous periods, forecasts and indicators of competitors.



Financial indicators
Gross profit
-
Net income
-27.29M
Accounts payable
129K
Accounts receivable
-
EPS
-0.87
Long-term debt
1.22M


Multipliers are coefficients, derivative financial indicators that allow for assessing financial stability, the degree of undervaluation, overvaluation, investment attractiveness of a company, company’s performance, and forecasting an increase or decline in the value of shares.



Multipliers
EV
-72.25M
EV/R
-
P/E
-1.25
EV/EBITDA
0.57
EBITDA
-30.4M
P/S
-
Profit margin
-
P/B
0.56
Operating margin
-
Total debt
1.59M
Annual revenue per share
-
Debt to equity ratio
1.22
ROE
-0.64
Current liquidity coefficient
5.37
ROA
-0.38
Ratio of short positions to the total shares in circulation
0.04
Forward P/E
-0.97
Forward annual dividend yield
-
PEG
-0.97
Operating cash flow
-100.75M

Athira Pharma stock forecast for today, ATHA signals for 1 week

Short-term ATHA price forecast (signals) are prepared by Traders Union based on the technical analysis of moving averages and indicators for each timeframe (interval) separately. Select the timeframe that you need to learn the ATHA forecast for today.

NOTE!

Signals may differ on different time frames. If you want to buy Athira Pharma (ATHA) and hold the stock for longer than one week, it is best to use the signals on daily and weekly timeframes. Timeframes from 5 minutes to 1 hour are best suitable for short-term transactions!

Invest in US Stocks
Your capital is at risk.

Best commission-free broker for stock investments

Suitable for those who want to invest in the stocks for the long term

Athira Pharma Stock forecast for 1 year. What will the ATHA price be?

In this section, you will learn the following analyst forecasts:


  • Projected stock value
  • Quarterly and annual earnings per share (EPS) forecast.

The forecasts are made based on surveys of top managers of companies and analysts. Also, current financial indicators of companies and projected indicators were taken into account.

Recommendations of analysts
Strong Buy 4
Buy 6
Hold 6
Sell 0
Strong Sell 0
Overall recommendation Buy
Projected stock value for six months, USD
Current stock price 1.95
Highest projected stock price 19
Lowest projected stock price 3
Average projected stock price 6.9
Quarterly and annual earnings per share (EPS) forecast, USD
Parameter Current quarter forecast 12-month forecast
Maximum forecast -0.74 -0.64
Minimum forecast -0.88 -3.58
Parameter Current quarter forecast 12-month forecast
Average forecast -0.79 -1.97
Average forecast value 1 year ago -0.78 -3.24

Indicator Based Technical Analysis of ATHA/USD

To find a better entry point, also find out what TradingView technical analysis tool signals for the Athira Pharma (ATHA/USD) price. "Sell" or "Strong Sell" means that most of the signals are bearish. "Buy" or "Strong Buy" means that most of the signals are bullish. For short-term signals, it is recommended to use settings from 15 minutes to 2 hours. For long-term signals, it is recommended to use settings from 4 hours to 1 week.

ATHA/USD Chart Online

What Athira Pharma price will be in 5 years and 12 years – prediction by years

According to the Traders Union long-term price forecast Athira Pharma (ATHA) can reach $2.94 by 2025, $11.18 by 2030, $32.52 by 2034.

Year Price in the middle of the year Price at the end of the year
2024 $2.55 $2.94
2025 $3.33 $3.84
2026 $4.35 $5.02
2027 $5.68 $6.55
2028 $7.42 $8.56
2029 $9.69 $11.18
2030 $12.66 $14.6
2031 $16.53 $19.06
2032 $21.59 $24.9
2033 $28.2 $32.52
2034 $36.83 $42.47
2035 $48.1 $55.46

Alternative long-term price forecasts by independent analytical platforms

Here, you will find long-term stock price forecasts provided by independent analytical resources. The price forecasting methodologies they use vary, which is why the forecasts may differ substantially from each other. We recommend focusing on the average price.


According to the price forecast by Walletinvestor analysts, the Athira Pharma stock will be priced at $1.079 at the beginning of 2025, and $0.000001 at the beginning of 2028.


What Athira Pharma (ATHA) news can influence the price in the future?

Athira Pharma is a venture asset that could both succeed and fail. The history of biopharmaceutical companies has examples, when the stock price of companies doubled or tripled in a matter of months, followed by successful clinical trials, for example Pfizer. There have been failures as well, for example Theranos. The situation with Athira Pharma is similar: if the company presents real results of its research and its products pass clinical trials successfully, obtaining corresponding certificates, the stock price will rise by more than ten times. However, the company has not shown successful results of its developments for over 12 years, which is why its stock price continues to fall.

Latest exchange rates online

Price prediction methodology

The following tools and instruments were used for making the prediction:


Basic instruments of technical analysis. The forecast relies on basic technical indicators. The analysis was performed mostly on medium and long-term time frames for more accurate results.

Chart analysis. Analysis comprises a review of key levels of support, resistance, trend lines, as well as patterns formed on different time frames.

Statistical tools help evaluate a probability of a fundamental factor that could impact the price, its nature and intensity of impact.

Methods of mathematical and statistical analysis; modeling, adaptive forecasting methods.

Expert opinions and consensus forecast.

NOTE!

This forecast is based on current information and data of previous periods. Emergence of strong fundamental factors capable of radically changing the overall market trend and subsequent price trend is possible. The forecasts are updated regularly based on the latest data.

This article is created for informational purposes only and does not constitute investment advice. Be aware of the high volatility of cryptocurrencies and consider these risks when making investment decisions.

FAQs

Is Athira Pharma a good stock to Buy?

No. It is a venture stock that so far has been showing only a negative trend. It is a high-risk asset.

Why is Atha stock dropping?

The company is involved in developments in the area of biopharmaceuticals. Since its incorporation, the company has not had a breakthrough, which is why investors are starting to lose trust and patience.

Is ATHA stock a good Buy?

At the moment, the stock price is falling, so there is no sense in buying it. However, it is worth monitoring this stock. If the company achieves positive results of the research that will be useful to society, investors should consider buying the stock.

What is the future of ATHA stock?

Everything depends on what developments the company will be able to offer. The path of Theranos is one of possible scenarios.